Diagnostics

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Venture firm JVP leverages its strategic focus on vertical AI and cybersecurity, cashing in on four major portfolio exits in a landmark first quarter.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Crossroads Counselling expands psychoeducational testing to age 30, addressing a critical gap in care amid long public waits and high academic pressures.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Diagnostics Direct wins a Johns Hopkins award for a rapid test that detects active syphilis, promising same-day diagnosis and treatment to combat rising rates.

Following a record year of profit and growth, the French diagnostics firm secures a major analyst endorsement, signaling a powerful turnaround. What's next?

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Lighten and Datavant have teamed up to turn messy medical notes into regulatory-grade data, aiming to dramatically speed up life sciences research.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

Koelis launches ProMap® Smart, an AI software that contours the prostate in under 5 seconds, boosting biopsy precision and streamlining patient care.

On May 18, competitors like Ulta and CVS join forces for National Sun Responsibly Day, an urgent call to make daily sun protection a life-saving habit.

Beyond just tracking data, SIBIONICS's new AI tools aim to tell diabetes patients what to do next, heralding a new era of personalized care.